Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as OncoGenex in the filing text) on March 8, 2012. The report discloses financial results for the fourth quarter and full year ended December 31, 2011, and provides updates on the development program for Custirsen in advanced prostate cancer in collaboration with Teva Pharmaceutical Industries Ltd.
Key Financial Metrics
The filing text references a press release (Exhibit 99.1) containing the specific financial results for the fourth quarter and year ended December 31, 2011. However, the text of this Form 8-K does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached exhibits, which are not included in the provided source text.
Material Changes
The filing does not explicitly detail numerical material changes versus prior periods within the body text. It indicates that the Company issued a press release announcing results for the period ended December 31, 2011, but specific comparative data is absent from this summary document.
Guidance, Outlook, and Material Events
- Regulation FD Disclosure: On March 8, 2012, OncoGenex and Teva Pharmaceutical Industries Ltd. issued a joint press release titled "Teva and OncoGenex Announce Updates to Custirsen Development Program in Advanced Prostate Cancer."
- Financial Results: The Company announced its financial results for Q4 and the full year 2011 via a press release (Exhibit 99.1).
- Legal Status of Information: The information in Items 2.02 and 7.01 and the associated exhibits is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash position figures in Exhibit 99.1 (Press Release dated March 8, 2012).
- Review Exhibit 99.2 for detailed clinical trial updates and strategic implications of the Custirsen program with Teva.
- Confirm the company's current cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical company but are not listed in the 8-K text.
- Check for any subsequent filings regarding the Custirsen program outcomes or additional financing activities.